Agios Pharmaceuticals, Inc. AGIO R2K
Healthcare · Biotechnology · United States
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
READ MORE ›$29.40
-8.38% 1Y
Market & Price
Market Cap
$1.75B
Current Price
$29.40
High / Low (52W)
$45.49 / $22.34
Beta
0.58
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$18.69
Price to Book
1.57
P/S
26.47
EV/EBITDA
-2.23
Dividend Yield
-
Profitability & Returns
ROCE
-38.86%
ROE
-32.81%
ROA
-21.69%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-1.69
EPS (TTM)
$-7.26
Balance Sheet & Liquidity
Debt/Equity
3.22
Quick Ratio
12.80
Current Ratio
14.19
Debt
$35.74M
Total Assets
$1.30B
Current Assets
$942.05M
Working Capital
$859.85M
Ownership
Promoter Holding
1.09%
Chg in Prom Hold
-
FII / Inst Holding
108.61%
Chg in FII Hold
-0.04%
Financial Snapshot
Enterprise Value
$1.05B
Total Revenue (TTM)
$66.05M
EBITDA
$-470.27M
Free Cash Flow
$-267.22M
Operating Cash Flow
$-380.41M
Shares Outstanding
59.47M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
55.97%
Profit 5Y
-26.03%
Revenue (YoY)
137.70%
Earnings (YoY)
-
PROS
- Compounding revenue at 56.0% over 5 years.
CONS
- Earnings shrank at -26.0% CAGR over 5 years.
- Trading 35.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGIO Agios Pharmaceuticals, Inc. R2K | 29.40 | - | $1.75B | - | -38.86% | -32.81% | 55.97% | -26.03% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 11.36M | - | 8.76M | 40.41M | 15.20M | 30.01M | 30.23M | 26.22M | 26.02M | 35.44M | 87.10M | 37.35M | 34.71M | 44.05M | 0 | 0 | 0 | - | 832.00K | 5.58M | 3.52M | 5.61M | 6.71M | 7.40M | 8.19M | 8.62M | - | - | 8.73M | 12.46M | 12.88M | 19.97M | 20.75M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08M | 1.70M | 1.68M | 1.88M | 1.32M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.64M | 10.75M | 11.20M | 18.09M | 19.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.27M | 137.81M | 128.07M | 139.67M | 129.45M |
| Operating Income | -40.90M | -23.59M | -56.47M | -63.51M | -57.41M | -67.05M | -84.60M | -79.02M | -90.13M | -94.01M | -72.95M | -99.16M | -96.36M | -97.48M | -113.86M | -109.06M | -105.93M | -87.03M | -83.26M | -80.29M | -92.43M | -91.22M | -91.22M | -91.15M | - | -101.14M | -97.64M | -91.09M | -90.61M | -93.70M | -100.90M | -92.07M | -105.82M | - | - | -106.63M | -127.06M | -116.87M | -121.58M | -110.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.35M | -125.80M | -115.50M | -120.31M | -108.66M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -89.29M | -112.02M | -103.43M | -109.06M | -99.11M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.12M | -8.88M | - | - | 0 | -1.02M | - |
| Net Income | - | -23.20M | -55.95M | -62.83M | -23.20M | -66.17M | -83.08M | -77.14M | - | -90.83M | -68.75M | -94.66M | - | -93.08M | -109.87M | -106.17M | - | -40.26M | -90.48M | -98.98M | - | 1.87B | -86.22M | -88.77M | - | -94.77M | -91.81M | -81.75M | -81.02M | -83.81M | -91.32M | -81.55M | -96.12M | - | - | -89.29M | -112.02M | -103.43M | -108.04M | -99.11M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.59 | -1.31 | -1.43 | -1.41 | 26.95 | -1.41 | -1.56 | -1.74 | -1.74 | -1.68 | -1.49 | -1.47 | -1.51 | -1.64 | -1.45 | -1.69 | 16.22 | - | -1.55 | -1.93 | -1.78 | - | -1.69 |
| R&D Expense | - | 44.04M | 50.80M | 60.64M | - | 62.73M | 79.82M | 72.92M | - | 78.22M | 86.73M | 82.56M | - | 95.58M | 107.39M | 101.67M | - | 55.36M | 54.09M | 51.94M | - | 57.67M | 62.01M | 64.00M | - | 70.12M | 74.52M | 64.97M | 67.30M | 68.89M | 81.84M | 68.62M | 77.40M | 72.45M | - | 72.74M | 91.94M | 86.80M | - | 81.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 69.89M | 43.01M | 94.39M | 117.91M | 0 | - | 14.24M | 26.82M | 36.50M | 54.03M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 2.88M | 4.17M | 6.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 12.54M | 23.94M | 32.33M | 47.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 401.58M | 415.43M | 458.07M | 519.82M |
| Operating Income | -16.63M | -23.00M | -38.88M | -54.13M | -118.70M | -200.99M | -320.79M | -362.48M | -316.27M | -335.92M | - | -389.05M | -391.49M | -425.74M | -472.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -380.48M | -384.86M | -420.08M | -466.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -231.80M | -352.09M | 717.97M | -413.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 44.24M | -1.02M |
| Net Income | -23.71M | -20.10M | -39.41M | -53.50M | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -327.37M | - | -231.80M | -352.09M | 673.73M | -412.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | -6.86 | -4.74 | - | -4.23 | -6.33 | 11.64 | -7.12 |
| R&D Expense | 31.25M | 41.04M | 54.50M | 100.37M | 141.83M | 220.16M | 292.68M | 341.32M | 214.26M | 220.81M | 256.97M | 279.91M | 295.53M | 301.29M | 339.54M |
Compounded Sales Growth
| 5 Years: | 55.97% |
| 1 Year: | 137.70% |
Compounded Profit Growth
| 5 Years: | -26.03% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -8.38% |
| 6 Months: | +3.41% |
| 3 Months: | -2.75% |
| 1 Month: | +4.81% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.01M | 201.21M | 491.90M | 420.06M | 619.09M | 614.40M | 858.46M | 890.74M | 852.95M | - | 1.24B | 937.12M | 1.66B | 1.30B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 832.77M | 833.84M | 965.60M | 942.05M |
| Cash & Equivalents | 77.88M | 117.66M | 91.30M | 71.56M | 14.03M | 71.76M | 160.75M | 102.72M | 70.50M | 80.93M | 127.44M | - | 139.26M | 88.20M | 76.25M | 89.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 8.49M | 19.08M | 27.62M | 32.92M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 2.21M | 2.81M | 4.11M | 10.58M |
| Total Liabilities | - | - | - | - | - | - | 260.50M | 238.89M | 170.92M | 250.21M | 453.45M | - | 137.90M | 126.10M | 122.24M | 104.11M |
| Current Liabilities | - | - | 35.11M | 36.93M | 61.09M | 52.89M | 88.43M | 94.94M | 93.50M | 92.89M | 94.39M | - | 62.63M | 67.95M | 81.16M | 82.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 85.66M | 72.00M | 56.99M | 40.21M |
| Total Equity | -29.59M | -52.78M | -72.02M | 131.48M | 424.37M | 345.12M | 358.59M | 375.50M | 687.54M | 640.53M | 399.50M | - | 1.10B | 811.02M | 1.54B | 1.19B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.26M | 72.16M | 73.37M | 74.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.22M | -49.55M | -56.40M | - | -76.95M | 38.56M | -285.23M | -304.42M | -370.62M | -290.76M | - | -309.48M | -296.06M | -389.84M | -372.98M |
| Investing Cash Flow | -22.36M | 23.04M | -87.22M | - | 128.31M | -119.35M | -57.91M | -273.82M | 91.44M | 75.75M | - | 243.26M | 239.57M | 363.44M | 377.18M |
| Financing Cash Flow | 77.36M | 142.00K | 123.88M | - | 6.37M | 169.78M | 285.11M | 546.02M | 289.61M | 261.52M | - | 2.35M | 5.43M | 14.44M | 8.68M |
| Capital Expenditure | -1.91M | -1.48M | -1.29M | -2.22M | -20.16M | -9.91M | -4.63M | -6.99M | -12.03M | -14.11M | - | -4.88M | -18.50M | -1.69M | -14.32M |
| Free Cash Flow | -17.12M | -51.02M | -57.69M | - | -97.11M | 28.65M | -289.86M | -311.41M | -382.65M | -304.87M | - | -314.36M | -314.56M | -391.53M | -387.29M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -63.87M | -51.05M | -11.96M | 12.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating Margin % | - | - | - | - | - | -287.6% | -745.8% | -384.0% | -268.2% | - | - | -2,732.1% | -1,459.5% | -1,166.5% | -873.9% |
| Net Margin % | - | - | - | - | - | -284.0% | -731.6% | -366.6% | -349.0% | - | - | -1,627.8% | -1,312.6% | 1,845.9% | -764.0% |
| ROE % | 44.9% | 27.9% | -30.0% | -12.6% | -34.1% | -55.3% | -83.8% | -50.3% | -64.2% | -81.9% | - | -21.1% | -43.4% | 43.7% | -34.6% |
| ROCE % | - | -22.6% | -23.7% | -12.6% | -32.3% | -37.9% | -61.8% | -47.4% | -39.6% | -44.3% | - | -33.1% | -45.0% | -26.9% | -38.9% |
Shareholding Pattern
Insiders
1.09%
Institutions
108.61%
Public Float
109.81%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.68% | 5.75M | $169.20M |
| 2 | Farallon Capital Management LLC | 9.56% | 5.68M | $167.11M |
| 3 | State Street Corporation | 5.66% | 3.36M | $98.93M |
| 4 | Armistice Capital, LLC | 4.57% | 2.72M | $79.85M |
| 5 | Erste Asset Management GmbH | 4.55% | 2.70M | $79.52M |
| 6 | Shaw D.E. & Co., Inc. | 4.51% | 2.68M | $78.83M |
| 7 | Vanguard Capital Management LLC | 4.43% | 2.63M | $77.39M |
| 8 | Lynx1 Capital Management Lp | 4.39% | 2.61M | $76.78M |
| 9 | Vanguard Portfolio Management LLC | 4.39% | 2.61M | $76.76M |
| 10 | BNP Paribas Asset Management Holding S.A. | 2.66% | 1.58M | $46.48M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGIO
No recent headlines available.